gadoteridol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diagnostic agents, gadolinium derivatives 1268 120066-54-8

Description:

MoleculeDescription

Synonyms:

  • gadoteridol
  • Gadolinium-HP-DO 3A
  • ProHance
nonionic magnetic resonance contrast agent; structure given in first source
  • Molecular weight: 557.68
  • Formula: C17H28GdN4O7
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.50 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 16, 1992 FDA BRACCO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 596.63 53.68 115 2258 4657 46679032
Skin hypertrophy 255.93 53.68 53 2320 3058 46680631
Skin induration 240.75 53.68 50 2323 2924 46680765
Skin tightness 205.29 53.68 46 2327 3847 46679842
Fibrosis 117.76 53.68 29 2344 3635 46680054
Skin fibrosis 106.83 53.68 21 2352 924 46682765
Joint range of motion decreased 88.30 53.68 32 2341 15092 46668597
Skin hyperpigmentation 84.22 53.68 24 2349 5258 46678431
Scar 83.72 53.68 29 2344 11990 46671699
Anhedonia 76.11 53.68 26 2347 10309 46673380
Anaphylactic reaction 70.83 53.68 40 2333 53072 46630617
Emotional distress 69.46 53.68 33 2340 30674 46653015
Contrast media reaction 64.68 53.68 14 2359 991 46682698
Skin discolouration 64.52 53.68 32 2341 32648 46651041
Peau d'orange 60.81 53.68 10 2363 156 46683533
Joint contracture 53.90 53.68 13 2360 1489 46682200

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 507.79 57.61 100 1525 4271 29946582
Skin induration 192.85 57.61 40 1585 2179 29948674
Skin hypertrophy 176.29 57.61 38 1587 2491 29948362
Skin tightness 172.90 57.61 36 1589 1996 29948857
Fibrosis 121.25 57.61 28 1597 2505 29948348
Joint range of motion decreased 120.93 57.61 33 1592 5812 29945041
Joint contracture 119.29 57.61 26 1599 1789 29949064
Scar 98.66 57.61 28 1597 5683 29945170
Skin fibrosis 96.60 57.61 20 1605 1073 29949780
Extremity contracture 84.65 57.61 17 1608 782 29950071
Deformity 83.96 57.61 19 1606 1549 29949304
Mobility decreased 75.94 57.61 34 1591 25965 29924888
Emotional distress 74.29 57.61 29 1596 15736 29935117
Anhedonia 67.89 57.61 23 1602 8346 29942507
Pain 67.35 57.61 63 1562 172578 29778275

Pharmacologic Action:

SourceCodeDescription
ATC V08CA04 VARIOUS
CONTRAST MEDIA
MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Paramagnetic contrast media
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals
FDA MoA N0000175862 Magnetic Resonance Contrast Activity
FDA EPC N0000180184 Paramagnetic Contrast Agent

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4020572 VUID
N0000148274 NUI
D01137 KEGG_DRUG
4020572 VANDF
C0060930 UMLSCUI
CHEBI:31643 CHEBI
CHEMBL1200593 ChEMBL_ID
DB00597 DRUGBANK_ID
C062402 MESH_SUPPLEMENTAL_RECORD_UI
6655 INN_ID
0199MV609F UNII
44144429 PUBCHEM_CID
25483 RXNORM
4220 MMSL
4773 MMSL
d03843 MMSL
004118 NDDF
353946009 SNOMEDCT_US
420600009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ProHance HUMAN PRESCRIPTION DRUG LABEL 1 0270-1111 INJECTION, SOLUTION 279.30 mg INTRAVENOUS NDA 24 sections
ProHance HUMAN PRESCRIPTION DRUG LABEL 1 0270-1111 INJECTION, SOLUTION 279.30 mg INTRAVENOUS NDA 24 sections